<DOC>
	<DOCNO>NCT02844530</DOCNO>
	<brief_summary>The investigator propose randomized phase 2 study evaluate 90Y-epratuzumab tetraxetan relapsed/refractory CD22+ B-ALL adult patient use recommended activity 370 MBq/m² x 2. order confirm investigator ' previous result . The cut-off 70 % expression CD22 chosen order propose protocol adult CD22+ B ALL relapse refractory disease . Indeed , median expression CD22 almost 100 % set patient document 70 100 % . RIT assess comparison standard care salvage chemotherapy regimen . Only three standard salvage chemotherapy regimen permit order avoid much bias comparative analysis clinical efficacy .</brief_summary>
	<brief_title>Study Evaluating Efficacy 90Yttrium-epratuzumab Adults With CD22+ Relapsed/Refractory B-ALL</brief_title>
	<detailed_description>The experimental treatment consist 2 injection 370 MBq/m2 90Y-epratuzumab tetraxetan fractionate RIT day 1 day 8 . The first infusion 90Y-epratuzumab tetraxetan co-injected six first patient Nantes 111In-epratuzumab tetraxetan dosimetry purpose . Subjects randomize receive standard care salvage chemotherapy/ immunotherapy regimen assign per investigator 's choice one follow chemotherapy/ immunotherapy regimen : 1 . FLAG +- anthracycline base regimen ( Idarubicin 10 mg/m2 day 1 , 3 ; fludarabine 30 mg/m2 day 1-5 , cytarabine 2 g/m2 day 1-5 ) . For subject 's &gt; 60 year : idarubicin 5 mg/m2 day 1,3 , fludarabine 20 mg/m2 day 1-5 , cytarabine 1 g/m2 day 1-5 . 2 . Clofarabine clofarabine base regimen . Clofarabine use single agent follow recommend prescribe information . Clofarabine combination base regimen use &gt; =20mg/m2/day 5 day . 3 . Hyper-C-VAd regimen : hyperfractionated cyclophosphamide 300 mg/m2 intravenously ( i.v . ) every 12 hour 6 dos Days 1 3 + vincristine 2 mg i.v.Days 4 11 ; doxorubicin 50 mg/m2 i.v . 24 hour via central venous catheter Day 4 ; dexa-methasone 40 mg daily Days 1 4 11 14 . 4 . Blinatumomab ( Blincyto® ) administer 28-day continuous infusion ( 9µg/d day 1-7 ; 28µg/d thereafter , follow 2 week rest 2 cycle . Patients hospitalize first 9 day first cycle least first 2 day second cycle . A second RIT cycle ( consolidation ) allow experimental group case response ( CR CRp ) . From ethical point view , also permit propose RIT experimental treatment control group case treatment failure relapse 6 month follow inclusion . Follow-up also 12 month RIT patient .</detailed_description>
	<mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
	<criteria>Age &gt; = 18 year old Philadelphia positive negative BALL ( OMS ) &gt; 5 % blast bone marrow without extramedullary disease CD22+ expression &gt; =30 % blast population Refractory BALL define : treatment failure 1 2 successive course induction therapy first relapse &lt; 6 month CR . First relapse , second third relapse . Unresponsive prior treatment &gt; =1 second/third ( dasatinib , nilotinib , bosutinib , ponatinib ) generation TKIs standard induction chemotherapy Ph+ BALL patient . Peripheral absolute lymphoblast count &lt; 10000/µL : hydroxyurea and/or steroids/vincristine treatment within 2 week randomization allow reduce circulate blast . ECOG ( Eastern Cooperative Oncology Group ) &lt; 2 Creatinine clearance &gt; = 50 ml/min ( Cockroft formula ) serum creatinine &lt; =1.5 x ULN Adequate hepatic function : total serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) except document Gilbert syndrome consider tumor relate ; &lt; =5 ULN transaminase except consider tumor relate Written informed consent Having receive previously Epratuzumab : case receive previously epratuzumab , patient free HAHA ( antiepratuzumab antibody ) . Patient affiliate beneficiary National Health Service Patients lymphoblastic lymphoma include satisfied eligibility criterion . Noninclusion criterion : TALL , patient Burkitt lymphoma Active Meningeal involvement Isolated extramedullary relapse CD22 expression tumor cell &lt; 30 % HIV positive Active Hepatitis B C Allogeneic transplantation within 12 week prior start chemo/immunotherapy RIT Active acute chronic GVHD , systemic treatment GVHD within two week treatment start . No chemotherapy/immunotherapy &lt; 2 week randomization except reduce circulate lymphoblast count . Left ventricular ejection fraction &lt; 45 % Contraindication 90Yepratuzumab tetraxetan Previous concurrent second malignancy except adequately treat basal cell carcinoma skin , curatively treat situ carcinoma cervix , curatively treat solid cancer , evidence disease least 2 year Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Participation time another study investigational drug use Absence write informed consent Pregnant breastfeed woman Women men without effective contraceptive barrier need</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult</keyword>
</DOC>